)
)
Actinium Pharmaceuticals Investor Relations Material
Latest events
Study Result
Actinium Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Actinium Pharmaceuticals Inc
Access all reports
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted radiotherapies. These therapies are designed to deliver cancer-killing radiation to patients with high unmet medical needs, particularly in oncology and hematology. Actinium's lead product candidate, I-131 apamistamab (Iomab-B), is in a pivotal clinical trial targeting elderly patients with relapsed or refractory acute myeloid leukemia for bone marrow transplant conditioning. Actinium Pharmaceuticals Inc. is based in New York, New York, and its shares are listed on the NYSE.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
ATNM
Country
🇺🇸 United States